<DOC>
	<DOCNO>NCT00456521</DOCNO>
	<brief_summary>The purpose study determine whether combination naltrexone SR bupropion SR safe effective treat obesity lead great weight loss give group lifestyle modification program group lifestyle modification alone .</brief_summary>
	<brief_title>A Safety Efficacy Study Naltrexone SR/Bupropion SR Placebo Overweight Obese Subjects Participating Intensive Behavior Modification Program</brief_title>
	<detailed_description>The combination group lifestyle modification counsel pharmacotherapy recently show result nearly twice average weight loss one year ( 12.1 kg ) pharmacotherapy alone ( sibutramine , 5.0 kg ) lifestyle modification counsel alone ( 6.7 kg ) . Combining pharmacotherapy comprehensive program diet , exercise group lifestyle modification counseling may provide best weight loss regimen . This study evaluate weight loss subject participate comprehensive program receive combination naltrexone SR bupropion SR , placebo .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Female male subject age 18 65 year ( inclusive ) Body mass index ( weight [ kg ] /height [ m² ] ) ≥30 ≤45 kg/m² subject uncomplicated obesity , BMI ≥27 ≤45 kg/m² subject control hypertension and/or dyslipidemia Nonsmoker use tobacco nicotine product least 6 month screen Normotensive ( systolic ≤140 mm Hg diastolic ≤90 mm Hg ) . Antihypertensive medication allow exception alphaadrenergic blocker , betablockers , clonidine . Medical regimen stable least 8 week . Lowdensity lipoprotein level &lt; 190 mg/dL triglyceride level &lt; 400 mg/dL . Medications treatment dyslipidemia allow long medical regimen stable least 8 week . No clinically significant abnormality serum albumin , blood urea nitrogen ( BUN ) , creatinine , bilirubin , calcium phosphorus Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) within 2.5 time upper limit normal ( ULN ) No clinically significant abnormality hematocrit , white blood cell ( WBC ) count , WBC differential , platelet Fasting glucose ≤126 mg/dL receive hypoglycemic agent No clinically significant abnormality urinalysis Thyroid stimulate hormone ( TSH ) within 1.5 time ULN normal triiodothyronine ( T3 ) , TSH normal limit Female subject childbearing potential negative serum pregnancy test An IDSSR score &lt; 2 individual item : 5 ( sadness ) , 6 ( irritability ) , 7 ( anxiety/tension ) , 18 ( suicidality ) IDSSR total score &lt; 30 Female subject childbearing potential nonlactating agree continue use effective contraception throughout study 30 day discontinuation study drug Completed food diary 6 7 consecutive day screen Able comply require study procedure schedule Able speak read English Provided write informed consent Obesity know endocrine origin ( e.g. , untreated hypothyroidism , Cushing 's syndrome , establish polycystic ovary syndrome ) Serious medical condition ( include limit renal hepatic insufficiency ; congestive heart failure , angina pectoris , myocardial infarction , stroke , claudication , acute limb ischemia ; history malignancy exception nonmelanoma skin cancer surgically cure cervical cancer ) Serious psychiatric illness ( e.g. , lifetime history bipolar disorder , schizophrenia psychosis , bulimia , anorexia nervosa ; current serious personality disorder , e.g. , borderline ; severe major depressive disorder , recent [ previous 6 month ] suicide attempt current active suicidal ideation , recent hospitalization due psychiatric illness ) Response bipolar disorder question indicate presence bipolar disorder . Required medication treatment psychiatric disorder ( exception shortterm insomnia ) within previous 6 month History drug alcohol abuse dependence within 1 year Type I Type II diabetes mellitus Baseline ECG correct QT ( QTc ) interval ( use Bazett 's formula &gt; 450 millisecond ( msec ) [ male ] &gt; 470 msec [ female ] ) presence clinically significant cardiac abnormality , include limited pattern consistent myocardial ischemia , electrolyte abnormality , atrial ventricular dysrhythmia significant conduction abnormality Received exclude concomitant medication : psychotropic agent ( include antipsychotic , antidepressant , anxiolytic , mood stabilizer anticonvulsant agent ) exception lowdose benzodiazepine hypnotic agent treatment insomnia ; anorectic weight loss agent ; overthecounter dietary supplement psychoactive , appetite weight effect ; alphaadrenergic blocker ; betablockers ; clonidine ; coumadin ; theophylline ; cimetidine ; oral corticosteroid ; topiramate , DepoProvera® ; smoke cessation agent ; regular use opioid opioidlike analgesic History surgical device ( e.g. , lap band ) intervention obesity History seizures etiology , predisposition seizure ( e.g. , history cerebrovascular accident , head trauma &gt; 5 minute loss consciousness , concussion symptom last &gt; 15 minute , brain surgery , skull fracture , subdural hematoma , febrile seizure ) History treatment bupropion naltrexone within precede 12 month History hypersensitivity intolerance bupropion naltrexone Used drug , herb , dietary supplement believe significantly affect body weight participated weight loss management program within one month prior baseline Loss gain &gt; 4.0 kilogram within previous 3 month Females pregnant breastfeed plan become pregnant study period within 30 day discontinue study drug Planned surgical procedure could impact conduct study Received investigational drug use experimental device procedure within previous 30 day Participated previous clinical trial conduct Orexigen Had condition opinion investigator make subject unsuitable inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Behavior Modification</keyword>
</DOC>